留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

超重可能是急性高山病的危险因素:一项Meta分析

熊娟,  鹿辉,  王荣,  贾正平

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(5): 433-437
熊娟, 鹿辉, 王荣, 贾正平. 超重可能是急性高山病的危险因素:一项Meta分析[J]. 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
引用本文: 熊娟, 鹿辉, 王荣, 贾正平. 超重可能是急性高山病的危险因素:一项Meta分析[J]. 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
shu
XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Overweight might be a risk factor of acute mountain sickness: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Overweight might be a risk factor of acute mountain sickness: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
shu

超重可能是急性高山病的危险因素:一项Meta分析

doi: 10.3969/j.issn.1006-0111.2018.05.011

  • 兰州总医院药剂科, 甘肃 兰州 730050

基金项目: 全军后勤科研项目（CWH17J012）；国家自然科学基金资助（81401552）

Overweight might be a risk factor of acute mountain sickness: a Meta-analysis

  • Department of Pharmacy, Lanzhou General Hospital, Lanzhou 730050, China

  • 摘要: 目的 超重也许是急性高山病（acute mountain sickness，AMS）的危险因素，但仍存在很多争议。因此，进行Meta分析研究超重在AMS发生中的作用。 方法 利用电子数据库系统检索研究超重与AMS相关性的文献（截至2018年2月28日）。利用Mantel-Haenszel随机效应模型进行数据整合。纳入文献的异质性由I2的值表示。以P<0.05为具有显著性差异。用Revman 5.0软件处理和分析数据，结果以95%置信区间森林图的形式表示。 结果 纳入研究的566名超重志愿者中有300名患AMS（53%），而1 006名非超重志愿者中只有338名患AMS（34%），超重志愿者患AMS的危险比率（risk ratio，RR）为2.02（95% CI 1.08~3.76，Z=2.21，P=0.03）。结果表明超重是AMS发生的一项危险因素。 结论 虽然需要进一步深入的研究来确认超重在AMS发生中的作用，但根据有限的研究提示，超重也许是AMS发生的危险因素。因此，超重个体在进入高海拔地区前，应当做好充分的预防措施来避免AMS的发生。
    Abstract: Objective Overweight might be a risk factor of acute mountain sickness (AMS) but its efficacy on developing AMS remained controversial. To study the role of overweight in AMS by a Meta-analysis. Methods A comprehensive literature search (last update, February 28th 2018) was carried out by searching electronic databases for full texts of studies which compared incidence of AMS in overweight with non-overweight individuals. The primary outcome measure for this meta-analysis was the incidence of AMS. Mantel-Haenszel random effect model was used to aggregate data. Heterogeneity of included trials was interpreted by I2 values. A α level of 0.05 was used as the level of significance. The results were reported in a forest plot with 95% CI. Revman 5.0 software provided by the Cochrane Collaboration was used for data processing and analysis. Results AMS occurred in 300 of 566 (53%) in overweight individuals and in 338 of 1 006 (34%) in non-overweight individuals. Compared with non-overweight individuals and independent of the baseline risk ratio (RR), the combined RR of developing AMS in overweight individuals was 2.02 (95% CI 1.08 to 3.76, Z=2.21, P=0.03). It was suggested that obese was a risk factor for developing AMS. The five included studies had high heterogeneity (I2=94%). Conclusion Although further in-depth studies were needed to confirm the function of overweight in the development of AMS, according to a limited number of studies, overweight might be a risk factor of AMS. Therefore, overweight individuals should be provided adequate prophylaxis against AMS before ascent to high altitude.
  • [1] BARTSCH P,SWENSON ER. Clinical practice:acute high-altitude illnesses[J].N Engl J Med, 2013, 368(24):2294-2302.
    [2] SCHNEIDER M, BERNASCH D, WEYMANN J, et al. Acute mountain sickness:influence of susceptibility, preexposure, and ascent rate[J].Med Sci Sports Exerc, 2002, 34(12):1886-1891.
    [3] FIORE DC, HALL S,SHOJA P. Altitude illness:risk factors, prevention, presentation, and treatment[J].Am Fam Physician, 2010, 82(9):1103-1110.
    [4] KAYSER B,VERGES S. Hypoxia, energy balance and obesity:from pathophysiological mechanisms to new treatment strategies[J].Obes Rev, 2013, 14(7):579-592.
    [5] ROACH RC, HOUSTON CS, HONIGMAN B, et al. How well do older persons tolerate moderate altitude[J].West J Med, 1995, 162(1):32-36.
    [6] RI-LI G, CHASE PJ, WITKOWSKI S, et al. Obesity:associations with acute mountain sickness[J].Ann Intern Med, 2003, 139(4):253-257.
    [7] HIRATA K, MASUYAMA S,SAITO A. Obesity as risk factor for acute mountain sickness[J].Lancet,1989,2(8670):1040-1041.
    [8] MCDEVITT M, MCINTOSH SE, RODWAY G, et al. Risk determinants of acute mountain sickness in trekkers in the Nepali Himalaya:a 24-year follow-up[J].Wilderness Environ Med, 2014, 25(2):152-159.
    [9] WU TY, DING SQ, LIU JL, et al. Who should not go high:chronic disease and work at altitude during construction of the Qinghai-Tibet railroad[J].High Alt Med Biol, 2007, 8(2):88-107.
    [10] YANG B, SUN ZJ, CAO F, et al. Obesity is a risk factor for acute mountain sickness:a prospective study in Tibet railway construction workers on Tibetan plateau[J].Eur Rev Med Pharmacol Sci, 2015, 19(1):119-122.
    [11] GAILLARD S, DELLASANTA P, LOUTAN L, et al. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal:a 12-year follow-up[J].High Alt Med Biol, 2004, 5(4):410-419.
    [12] WAGNER DR, FARGO JD, PARKER D, et al. Variables contributing to acute mountain sickness on the summit of Mt Whitney[J].Wilderness Environ Med, 2006, 17(4):221-228.
    [13] HIGGINS JP,THOMPSON SG. Quantifying heterogeneity in a meta-analysis[J].Stat Med, 2002, 21(11):1539-1558.
    [14] GERTSCH JH, LIPMAN GS, HOLCK PS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache:the Headache Evaluation at Altitude Trial (HEAT)[J].Wilderness Environ Med, 2010, 21(3):236-243.
    [15] GERTSCH JH, CORBETT B, HOLCK PS, et al. Altitude sickness in climbers and efficacy of NSAIDs trial (ASCENT):randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness[J].Wilderness Environ Med, 2012, 23(4):307-315.
    [16] LIPMAN GS, KANAAN NC, HOLCK PS, et al. Ibuprofen prevents altitude illness:a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories[J].Ann Emerg Med, 2012, 59(6):484-490.
    [17] HSU TY, WENG YM, CHIU YH, et al. Rate of ascent and acute mountain sickness at high altitude[J].Clin J Sport Med, 2015, 25(2):95-104.
    [18] WANG SH, CHEN YC, KAO WF, et al. Epidemiology of acute mountain sickness on Jade Mountain, Taiwan:an annual prospective observational study[J].High Alt Med Biol, 2010, 11(1):43-49.
  • [1] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [2] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [3] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [4] 史生辉, 石飞, 雷琼, 王亚峰, 吴雪花.  青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
    [5] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 1-8. doi: 10.12206/j.issn.2097-2024.202401073
    [6] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [7] 刘依秦, 王超群, 邱娇娜.  胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
    [8] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
    [9] 宋红卫, 王燕, 方铭, 马云鹏, 钟超, 徐一新, 徐峰, 周婷.  2021−2023年我院药品不良反应的特点分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404041
    [10] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [11] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
    [12] 尹小娟, 台力丽, 肖俊峰, 季波.  铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
    [13] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [14] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [15] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2725
  • HTML全文浏览量:  291
  • PDF下载量:  293
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-03-20
  • 修回日期:  2018-07-03

超重可能是急性高山病的危险因素:一项Meta分析

doi: 10.3969/j.issn.1006-0111.2018.05.011
  • 兰州总医院药剂科, 甘肃 兰州 730050
    • 基金项目:  全军后勤科研项目（CWH17J012）；国家自然科学基金资助（81401552）
  • 收稿日期: 2018-03-20
  • 修回日期: 2018-07-03

摘要: 目的 超重也许是急性高山病（acute mountain sickness，AMS）的危险因素，但仍存在很多争议。因此，进行Meta分析研究超重在AMS发生中的作用。 方法 利用电子数据库系统检索研究超重与AMS相关性的文献（截至2018年2月28日）。利用Mantel-Haenszel随机效应模型进行数据整合。纳入文献的异质性由I2的值表示。以P<0.05为具有显著性差异。用Revman 5.0软件处理和分析数据，结果以95%置信区间森林图的形式表示。 结果 纳入研究的566名超重志愿者中有300名患AMS（53%），而1 006名非超重志愿者中只有338名患AMS（34%），超重志愿者患AMS的危险比率（risk ratio，RR）为2.02（95% CI 1.08~3.76，Z=2.21，P=0.03）。结果表明超重是AMS发生的一项危险因素。 结论 虽然需要进一步深入的研究来确认超重在AMS发生中的作用，但根据有限的研究提示，超重也许是AMS发生的危险因素。因此，超重个体在进入高海拔地区前，应当做好充分的预防措施来避免AMS的发生。

English Abstract

熊娟, 鹿辉, 王荣, 贾正平. 超重可能是急性高山病的危险因素:一项Meta分析[J]. 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
引用本文: 熊娟, 鹿辉, 王荣, 贾正平. 超重可能是急性高山病的危险因素:一项Meta分析[J]. 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
shu
XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Overweight might be a risk factor of acute mountain sickness: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
Citation: XIONG Juan, LU Hui, WANG Rong, JIA Zhengping. Overweight might be a risk factor of acute mountain sickness: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
shu

    全文HTML

参考文献 (18)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计